Real-world safety of switching from originator to biosimilar natalizumab

被引：0

作者：

Brustad, Age Winje ^{[1
]}

Hogestol, Einar ^{[2
,3
,4
]}

Meling, Martine ^{[2
]}

Celius, Elisabeth Gulowsen ^{[2
,4
]}

Berg-Hansen, Pal ^{[2
]}

Konig, Marton ^{[2
,4
]}

Holterbakken, Trine Alm ^{[2
]}

Warren, David ^{[1
]}

Gehin, Johanna ^{[1
]}

Bolstad, Nils ^{[1
]}

Nygaard, Gro Owren ^{[2
,4
]}

机构：

[1] Oslo Univ Hosp, Dept Med Biochem, Oslo, Norway

[2] Oslo Univ Hosp, Dept Neurol, Oslo, Norway

[3] Oslo Univ Hosp, Dept Psychol, Oslo, Norway

[4] Univ Oslo, Inst Clin Med, Oslo, Norway

来源：

MULTIPLE SCLEROSIS JOURNAL | 2024年 / 30卷 / 03期

关键词：

D O I：

暂无

中图分类号：

R74 [神经病学与精神病学];

学科分类号：

摘要：

P1670/563

引用

页码：1056 / 1057

页数：2

共 50 条

[31] Analysis of the effectiveness and safety of switching from originator to biosimilar adalimumab in patients with Inflammatory Bowel Disease
Casanova, M. J.
Chaparro, M.
Nantes, O.
Varela, P.
Vela-Gonzalez, M.
Montserrat, R.
Sierra, O. G.
Riestra, S.
Barreiro-de Acosta, M.
Martin-Rodriguez, M. M.
Gargallo-Puyuelo, C. J.
Reygosa, C.
Munoz, R.
Garcia de la Filia-Molina, I.
Nunez-Ortiz, A.
Kolle, L.
Calafat, M.
Huguet, J. M.
Iglesias-Flores, E.
Martinez-Perez, T. J.
Bosch, O.
Duque-Alcorta, J. M.
Frago-Larramona, S.
Sanchez-Azofra, M.
Van Domselaar, M.
Gonzalez-Cosano, V. M.
Bujanda, L.
Rubio, S.
Mancebo, A.
Castro, B.
Garcia-Lopez, S.
de Francisco, R.
Nieto, L.
Laredo, V.
Gutierrez, A.
Mesonero, F.
Leo-Carnerero, E.
Canete, F.
Ruiz, L.
Gisbert, J. P.
JOURNAL OF CROHNS & COLITIS, 2022, 16 : I474 - I475
[32] Real-world treatment outcomes and safety of natalizumab in Finnish multiple sclerosis patients
Verkkoniemi-Ahola, Auli
Hartikainen, Paivi
Hassi, Katja
Kuusisto, Hanna
Lahdenpera, Sanni
Mehtala, Juha
Viitala, Matias
Ylisaukko-oja, Tero
Soilu-Hanninen, Merja
MULTIPLE SCLEROSIS JOURNAL-EXPERIMENTAL TRANSLATIONAL AND CLINICAL, 2023, 9 (04)
[33] Switching from Nusinersen to Risdiplam: A Croatian Real-World Experience on Effectiveness and Safety
Belancic, Andrej
Strbad, Tea
Stiglic, Marta Kucan
Vitezic, Dinko
JOURNAL OF PERSONALIZED MEDICINE, 2024, 14 (03):
[34] Real-World Comparative Analysis of Trastuzumab Originator and Biosimilars: Safety, Efficacy, and Cost Effectiveness
Mamori, Tomoka
Tanioka, Maki
Takada, Kenji
Hamano, Hirofumi
Tsukioki, Takahiro
Takahashi, Yuko
Iwatani, Tsuguo
Shien, Tadahiko
Toyooka, Shinichi
BIODRUGS, 2025, 39 (01) : 131 - 142
[35] Real-World Comparative Analysis of Trastuzumab Originator and Biosimilars: Safety, Efcacy, and Cost Efectiveness
Mamori, T.
Tanioka, M.
Takada, K.
Hamano, H.
Tsukioki, T.
Takahashi, Y.
Iwatani, T.
Shien, T.
Toyooka, S.
BREAST, 2025, 80
[36] Long-term Follow-up of Starting and Switching from Bio-originator to Biosimilar: Real-world Data in Axial Spondyloarthritis Patients Treated with Adalimumab and Etanercept
Fernandes, Ana Lucia Martins
Pinto, Ana
Flora, Kalveer
Matharu, Dilpreet
Isaacs, Anthony
Machado, Pedro
ARTHRITIS & RHEUMATOLOGY, 2022, 74 : 860 - 861
[37] Effectiveness and safety of natalizumab in real-world clinical practice: Review of observational studies
van Pesch, Vincent
Sindic, Christian J.
Fernandez, Oscar
CLINICAL NEUROLOGY AND NEUROSURGERY, 2016, 149 : 55 - 63
[38] INFLIXIMAB BIOSIMILAR-TO-BIOSIMILAR SWITCHING IN PATIENTS WITH INFLAMMATORY RHEUMATIC DISEASES: CLINICAL OUTCOMES IN REAL-WORLD PATIENTS FROM THE DANBIO REGISTRY
Nabi, H.
Hetland, M. L.
Loft, A. G.
Hendricks, O.
Jensen, D.
Pedersen, J. K.
Just, S. A.
Danebod, K.
Munk, H. L.
Kristensen, S.
Manilo, N.
Colic, A.
Linauskas, A.
Thygesen, P. H.
Christensen, L. B.
Kalisz, M. Hogberget
Lomborg, N.
Grydehoj, J.
Raun, J.
Ahmed, R.
Mehnert, F.
Krogh, N. Steen
Glintborg, B.
ANNALS OF THE RHEUMATIC DISEASES, 2022, 81 : 45 - 46
[39] SWITCHING TO BIOSIMILAR RITUXIMAB: A REAL WORLD STUDY
Nisar, Muhammad K.
RHEUMATOLOGY, 2019, 58
[40] SWITCHING TO BIOSIMILAR RITUXIMAB: A REAL WORLD STUDY
Nisar, Muhammad K.
RHEUMATOLOGY, 2018, 57

← 1 2 3 4 5 →